Companion diagnostics and molecular imaging

Cancer Journal (United States)

Volumn 21, Issue 3, 2015, Pages 213-217

  Puranik, Ameya D ^a   Kulkarni, Harshad R ^a   Baum, Richard P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Cancer patient; companion diagnostics (CDx); concept of theranostics; molecular imaging; treatment selection

Indexed keywords

ANGIOPEPTIN; BIOLOGICAL MARKER; CAPECITABINE; CRIZOTINIB; DOTATOC GA 68; DOTATOC LU 177; DOTATOC Y 90; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER PATIENT; CLINICAL LABORATORY; COMPANION DIAGNOSTIC DEVICE; COMPANION DIAGNOSTICS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DETERMINATION; DRUG MECHANISM; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOTOPE LABELING; METABOLOMICS; MOLECULAR DIAGNOSTICS; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; RADIOGRAPHY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERANOSTICS; TREATMENT OUTCOME; NEOPLASMS; PROCEDURES; THERANOSTIC NANOMEDICINE; UNITED STATES;

HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; THERANOSTIC NANOMEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930584536     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000110     Document Type: Review

References (30)

1. Vollmann J. Persönlicher-besser-kostengünstiger Kritische medizinethische Anfragen an die "personalisierte Medizin". Eth Med. 2013;25:233-241.
2. Schleidgen S, Marckmann G. Alter Wein in neuen Schlaüchen Ethische Implikationen der Individualisierten Medizin. Eth Med. 2013;25:223-231.
3. Schleidgen S, Klingler C, Bertram T, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55.
4. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist. 1999;4:426-427.
5. Jorgensen JT. New era of personalized medicine: a 10-year anniversary. Oncologist. 2009;14:557-558.
6. Jorgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov Today. 2011;16:891-897.
7. Parkinson DR, Cesano A. Patient-specific classifications of human malignant disease. Curr Opin Mol Ther. 2009;11:252-259.
8. Becker R Jr, Mansfield E. Companion diagnostics. Clin Adv Hematol Oncol. 2010;8:478-479.
9. Choi YL, Soda M, Yamashita Y, et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl JMed. 2010;363:1734-1739.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
11. GerberDE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18:548-551.
12. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106: 1100-1106.
13. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010; 28:2777-2783.
14. US Food and Drug Administration. Drug-Diagnostic Co-development Concept Paper. Food and Drug Administration (2005). Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/UCM116689.pdf.
15. Jørgensen JT. Companion diagnostics in oncology-current status and future aspects. Oncology. 2013;85:59-68.
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
17. Jørgensen JT, Winther H. The development of theHercepTest-from bench to bedside. In: Jørgensen JT, WinterH, eds. Molecular Diagnostics-The Key Driver of Personalized Cancer Medicine. Singapore: Pan Stanford Publishing; 2010:43-60.
18. US Food and Drug Administration. Companion Diagnostic Devices: In Vitro and Imaging Tools. 2013. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
19. Varond AJ. Trends in Personalized Medicine. Regulatory Focus 2013. Available at: http://www.raps.org/focus-online/news/news-article-view/article/4244/trends-in-personalized-medicine.aspx.
20. Food US, Administration Drug. Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development 2013. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/Personalized Medicine/UCM372421.pdf.
21. US Food and Drug Administration. In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff 2014. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf.
22. Iyer M, Sato M, Johnson M, et al. Applications of molecular imaging in cancer gene therapy. Curr Gene Ther. 2005;5:607-618.
23. Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J NuclMed. 2008;49(suppl 2):164S-179S.
24. Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62(suppl 1):S11-S14.
25. Pene F, Courtine E, Cariou A, et al. Toward theragnostics. Crit Care Med. 2009;37:S50-S58.
26. Ideé JM, Louguet S, Ballet S, et al. Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med Surg. 2013;3:292-297.
27. Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience. Theranostics. 2012;2:437-447.
28. Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin. 2014;9:91-97.
29. Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to theranostics. Dalton Trans. 2011; 40:6104-6111.
30. Kulkarni HR, Baum RP. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. PET Clin. 2014;9:83-90.